Revance Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • December 7th, 2017 • Revance Therapeutics, Inc. • Pharmaceutical preparations • New York
Revance Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,838,709 shares and, at the election of the Underwriters, up to 550,806 additional shares of common stock, $0.001 par value per share (“Stock”) of the Company and the stockholders of the Company named in Schedule I(a) hereto (the “Selling Stockholders”) propose, subject to the terms and conditions stated herein, to sell to the Underwriters an aggregate of 500,000 shares and, at the election of the Underwriters, up to 250,000 additional shares of Stock. The aggregate of 5,338,709 shares to be sold by the Company and the Selling Stockholders is herein called the “Firm Shares” and the aggregate of 800,806 additional shares to be sold by the Company and the Selling Stockholders is herein called the “Optional Shares”. The Firm Shares
